Previous 10 | Next 10 |
Primary Endpoint Met with Highly Statistically Significant Results No Observed Safety Issues Final Data R eadout Expected in Second Quarter of 2022 YAVNE, Israel, Jan. 24, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integra...
MediWound (NASDAQ:MDWD) announces positive initial data from seven of the maximum fifteen patients in its ongoing Phase 2 pharmacology study of EscharEx, the company’s next-generation enzymatic debridement agent under development for chronic and hard-to-heal wounds. Shares up 2.5%...
Data Demonstrate EscharEx Reduces Biofilm and Bacterial Burden EscharEx is Shown to be Safe with No Observed Safety Issues YAVNE, Israel, Dec. 20, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (the “Company”), a fully-integrated biopharmaceutical company...
YAVNE, Israel, Dec. 06, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (the “Company”), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced it has completed patient enrollm...
YAVNE, Israel, Nov. 18, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (the “Company”), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced that the Company has received po...
MediWound Ltd. (MDWD) Q3 2021 Results Conference Call November 16, 2021 08:30 AM ET Company Participants Monique Kosse - LifeSci Advisors Sharon Malka - CEO Boaz Gur-Lavie - CFO Conference Call Participants Bryan Bergin - Cowen and Company Ryan Zimmerman - BTIG Kevin DeGeeter - Oppenheimer Sw...
MediWound (NASDAQ:MDWD): Q3 GAAP EPS of -$0.12 beats by $0.01. Revenue of $6.37M (-3.9% Y/Y) beats by $0.7M. Press Release For further details see: MediWound EPS beats by $0.01, beats on revenue
Third Quarter Revenues of $6.4 Million ; Year-to-Date 2021 Revenues Increased 21% C larity on R egulatory P athway for R esubmission of NexoBrid BLA , A nticipated in M id- 2022 Escha...
MediWound (NASDAQ:MDWD) is scheduled to announce Q3 earnings results on Tuesday, November 16th, before market open. The consensus EPS Estimate is -$0.13 (-85.7% Y/Y) and the consensus Revenue Estimate is $5.67M (-14.5% Y/Y). Over the last 3 months, EPS estimates have seen 2 upward revisions a...
AQUA, ARMK, OTCPK:AWLCF, CAN, CWCO, DAO, DAVA, DOYU, ECC, ESEA, FLNG, FUV, GDS, HD, HIVE, OTCQX:IMBBY, JMIA, LILM, MDWD, NTES, OCSL, OZON, REE, SE, TDG, OTCQX:TRSSF, VOD, OTCQX:VYGVF, WMT, ZEPP For Seeking Alpha's full earnings season calendar, click here. For further details see: ...
News, Short Squeeze, Breakout and More Instantly...
Research Published in THE LANCET's eClinicalMedicine EscharEx ® Outperforms Non-Surgical Standard of Care in Debridement and Promotion of Healthy Granulation Tissue YAVNE, Israel, July 29, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in ne...
Funds to be used for clinical development of EscharEx ® to treat diabetic foot ulcers (DFUs) Award advances MediWound’s DFU program and its future revenues four years ahead of original schedule YAVNE, Israel, July 16, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd....
Mölnlycke® Health Care announces US $15m investment in next-generation enzymatic therapeutics company MediWound Ltd PR Newswire GOTHENBURG, Sweden , July 15, 2024 /PRNewswire/ -- Mölnlycke Health Care, a world-leading MedTech company specialising i...